Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics, Inc. announced the initiation of Part C of the ongoing DisTinGuish study to evaluate DKN-01, Leap’s DKK1 antibody, with tislelizumab, BeiGene’s anti-PD-1 antibody, and chemotherapy compared to a tislelizumab and chemotherapy control arm, in patients with gastric or gastroesophageal junction cancer.